Cancer therapy developer Antengene raises HK$2.64B in Hong Kong IPO

Antengene Corporation Ltd. closed its IPO on the Hong Kong Stock Exchange, raising net proceeds of about HK$2.64 billion.The Shanghai-based biopharmaceutical company is now officially listed on the exchange and its shares have commenced trading on the Main Board.

Antengene had offered 154,153,500 shares in its global offering — consisting of a Hong Kong offering and an international offering — at HK$18.08 per share. The final number of offer shares under the Hong Kong public offering and the international offering was 77,077,000 and 77,076,500, respectively.

The Hong Kong offering was 246.76 times oversubscribed, while the international offering was oversubscribed by 13.5 times.